바이오인

 
[바이오] 제24회 바이오 혁신 세미나(24023,온라인) [주제 : 오픈인슐린프로젝트]

1. 일시 및 장소
○ 일시 : 2024년 8월 23일(금) 중 09:00~11:00
○ 장소 : 온라인(줌)

2. 세미나 개요(세미나는 영어로 진행되며, 별도 통역없음)
OPEN INSULIN Project:
오픈인슐린 프로젝트는 상용화된 인슐린 제제와 동일한 품질의 인슐린제제를 각 국가 및 지자체에서 자체 수급 가능하도록 지원하는 비영리단체인 OPEN ISULIN FOUNDATION의 프로젝트임.
Open Insulin Foundation은 인슐린제제를 시작으로 필수 생존을 위한 치료제를 상용화되는 제품과 동일한 품질로 자체수급 가능하도록 지원하는 것을 목표로 한다.
2015년 Dr. Anthony Di Franco가 창립한 Open Insulin Foundation은 불필요하게 높은 가격인 인슐린제제의 가격 거품을 없애 더 많은 당뇨병환자들에게 easy access를 제공하는 것을 목표로 삼고 인슐린 제재의 특허문제, 생산문제 등을 해소하여 미국내 주 단위 생산시설을 확립하는 것을 추구하고 있다.
창업자인 Dr. Anthony di Franco와 인슐린제제의 생산관련 자문을 하고 있는 Dr. Roger Erickson이 연자로 Open Insulin Project의 현재와 앞으로 나아갈 방향에 대해서 소개하고자 함.

좌장 : 이주연(메드클라리스 대표)

09:00 – 09:45: 오픈 인슐린 프로젝트 – Lessons and Prospects in Organizing Open Medicine
(Dr. Anthony di Franco, Founder of Open Insulin Project)

[주요내용]
Anthony will speak about the history, context, and distinctive strategy of Open Insulin, the broader incentives and constraints in medicine, and implications for curing diabetes and progress on other so far intractable medical issues.

[연자 약력]
Anthony Di Franco is founder and president of the Open Insulin Foundation, an effort to make local scale production of insulin and other essential biologic medicines on an open source basis feasible. A type 1 diabetic himself, he maintains an active interest in developing a gene therapy for diabetes, which he is in the process of pursuing in a new venture. Anthony is also researching purely declarative probabilistic-relational languages with applications in verified computing, computer security, and agent-based software systems in view. Previously, he researched numerical computation, purely declarative probabilistic-relational programming languages, and other topics at the intersections of programming languages and machine learning in the PhD program at UC Davis. Anthony holds a BS in Physics and a BS in Computer Science and Mathematics from Yale University, where he studied control theory, statistics and information theory, and neural networks.

09:45-10:00: Q&A

10:00 - 10:45 : 지속가능한 생산시스템을 통한 오픈 인슐린 실현(Dr. Roger Erickson, Founder of Interbiome Partners)
10:00 - 10:45: Interbiome is working to enable universal access to reliable, clinical-dosing of the Open Insulin product, by establishing a worldwide franchise system providing STABLE AND DISTRIBUTED MANUFACTURING PROCESSES, for regional production of any and all needed pharmaceutical products. In addition to OpenInsulin, this Public Utility Standards approach to will manufacture products that regional populations need, but private investors will not make (Dr. Roger Erickson, Founder of Interbiome Partners).

[주요내용]
오픈 인슐린 프로젝트에서 개발한 인슐린제재 발현 세포주를 활용하여 중소 규모의 생산시설 및 시스템을 확립하고 운영가능한 인력을 교육하는데 집중을 하고 있으며, 이에 대한 현황을 설명할 예정임
세포기반 제재의 생산전문가이자 Interbiome Partners의 창업자로 지속가능한 생산시스템을 통해 필수 치료제 생산 및 공급을 환자에게 전달할 수 있도록 하고자 함
Interbiome is currently working with the OpenInsulin Foundation to finalize Process Development and establish a stable Tech Transfer platform and protocol. In this way the foundations developed by the Open Insulin Project can become available via documented Tech Transfer through any Interbiome franchise worldwide.

[연자약력]
Roger G. Erickson, PhD.
Interbiome Partners, LLC; Maryland, USA
Dr. Erickson is the founder of a holding company created to provide Stable, Distributed Drug Manufacturing franchises worldwide.
Dr. Erickson began his career in neurophysiology research in Portland, Oregon, received his PhD from SUNY/Buffalo, held post-doctoral fellowships in Tubingen, Boston and Connecticut, and was a Sr. Staff Fellow at the NIMH in Maryland. He has since enlarged his interests from neural systems to community and Population Health systems and has pioneered use of Contract Drug Manufacturing franchises as a vehicle for adaptive evolution of Population Health Supply Chains. Dr. Erickson has launched the Interbiome platform as a method for introducing a more distributed, Public Utility approach to providing many needed but missing, delayed and/or abandoned pharmaceutical products which profit-maximizing investors will not provide. The Interbiome approach bridges short-term profit-seeking and long-term coordination, by building and sustaining an affordable, distributed Reserve Capacity of both Human and Physical Capital.
Personal Background:
Roger Erickson grew up in Portland, Oregon, received a BA-Biology from Reed College, and a PhD-Physiology from SUNY-Buffalo. His research experiences include fellowships at the Alexander von Humboldt Stiftung in Germany, MIT Brain & Cognitive Sciences, Yale Medical School, and the National Institute of Mental Health.

10:45-11:00: Q&A

3. 참가비용 : 무료
4. 주최 : 충북바이오헬스산업혁신센터, 정밀의료의료기기 사업단(교통대)
5. 주관 : (재)베스티안재단, 충북바이오산학융합원
6. 후원 : 오송바이오헬스협의회(OBHA)
6. 참석대상자 : 충북 바이오산업계 인사를 포함한 바이오산업에 관심 있는 사람 등

...................(계속)

☞ 자세한 내용은 내용바로가기 또는 첨부파일을 이용하시기 바랍니다.